Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-3379 and Cetuximab in Advanced HNSCC
NCT03254927Phase 2Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cdx-3379 in head and neck squamous cell carcinoma (HNSCC), sponsored by Celldex Therapeutics. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2018; status: terminated.
02
Drugs
cdx-3379
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03254927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254927.